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Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL) and HTLV-
1-associated myelopathy/tropical spastic paraparesis in small subsets of HTLV-1 carriers.
HTLV-1-speciﬁc T-cell responses play critical roles in anti-viral and anti-tumor host defense
during HTLV-1 infections. Some HTLV-1 carriers exhibit selective loss or anergy of HTLV-1-
speciﬁc T-cells at an asymptomatic stage. This is also observed in ATL patients and may
therefore be an underlying risk factor of ATL in combination with elevated proviral loads.
HTLV-1-speciﬁc T-cells often recognize the viral oncoprotein Tax, indicating expression of
Tax protein in vivo, although levels of HTLV-1 gene expression are known to be very low.
A type-I interferon (IFN) response can be induced by HTLV-1-infected cells and suppresses
HTLV-1 expression in vitro, suggesting a role of type-I IFN response in viral suppression
and pathogenesis in vivo. Both acquired and innate immune responses control the status
of HTLV-1-infected cells and could be the important determinants in the development of
HTLV-1-mediated malignant and inﬂammatory diseases.
Keywords: adult T-cell leukemia, cytotoxic T lymphocytes, human T-cell leukemia virus type 1, HTLV-1-associated
myelopathy/tropical spastic paraparesis, type-I interferon
INTRODUCTION
Human T-lymphotropic virus type I (HTLV-1) causes adult T-cell
leukemia (ATL) (Hinuma et al., 1981; Uchiyama,1997) andHTLV-
1-associated myelopathy/tropical spastic paraparesis (HAM/TSP;
Gessain et al., 1985; Osame et al., 1986) in a subset of infected
individuals.While ATL is amalignant lymphoproliferative disease,
HAM/TSP presents as a chronic inﬂammatory neurodegenerative
disease. It is not known how one virus can cause two vastly differ-
ent diseases. Since no disease-speciﬁc difference among HTLV-1
strains have been identiﬁed (Daenke et al., 1990; Kinoshita et al.,
1991), the different pathogenic consequences must be attributed
to host factors. Indeed, the two diseases usually occur in different
populations of HTLV-1 carriers. Identiﬁcation of the determi-
nant factors may allow the prediction of disease risks and also the
development of prophylactic and therapeutic strategies.
One of the factors that are known to differ between ATL
and HAM/TSP patients is the strength of HTLV-1-speciﬁc T-cell
responses. T-cell responses are activated in HAM/TSP patients,
but are weak in ATL patients, and are thus considered to be one
of the most important determinants of the disease manifesta-
tion. Many investigators, including us, have been investigating
HTLV-1-speciﬁc cytotoxic T lymphocyte (CTL) responses, and
demonstrated the importance of these CTLs on anti-viral and
anti-tumor surveillance in HTLV-1-infected hosts (Jacobson et al.,
1990; Bangham and Osame, 2005; Kannagi et al., 2005). Based on
these studies we concluded that a reduced HTLV-1-speciﬁc T-cell
response can be an underlying risk factor for the development
of ATL.
Another difference between HAM/TSP and ATL patients is the
level of HTLV-1 gene expression. Although HTLV-1 mRNA levels
are generally low in vivo, they are slightly higher in HAM/TSP
patients compared with asymptomatic HTLV-1 carriers (ACs;
Yamano et al., 2002). The mechanism causing low levels of HTLV-
1 gene expression in vivo remains unknown. However, we recently
demonstrated that HTLV-1 expression is suppressed by non-
lymphoid stromal cells through type-I interferon (IFN), indicating
that innate immune responses can be another host determinant
for HTLV-1-induced diseases (Kinpara et al., 2009). So far there
have only been a limited number of studies reporting a type-I IFN
response during HTLV-1 infection.
The status of HTLV-1 expression is critical for host immune
responses and viral pathogenesis. In particular, HTLV-1 Tax is
a multipotent protein that is a main target of T-cell immunity
(Jacobson et al., 1990; Kannagi et al., 1991) and can activate NF-
κB, a characteristic transcriptional factor in ATL cells and a strong
inducer of inﬂammatory cytokines (Yoshida, 2001; Jeang et al.,
2004; Grassmann et al., 2005). The status of Tax expression in
vivo has been controversial but would be an extremely important
factor tomeasure in order to understand themechanism of disease
development in HTLV-1 infection. Expression of HTLV-1 basic
leucine zipper factor (HBZ) encoded by theminus-strandHTLV-1
genome is also an important factor for viral pathogenesis as HBZ
elicits indirect effects on tumor development and inﬂammation
(Satou et al., 2011).
In this review, we aim to understand the conﬂicting ﬁndings
that have been reported in regard to HTLV-1 expression in vivo.
We then describe recent ﬁndings that add to the knowledge about
well-characterized host T-cell responses, followed by a description
of the mechanisms that control viral expression. We ﬁnally dis-
cuss the relationship between HTLV-1 expression, host immune
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response, and HTLV-1-mediated malignant and inﬂammatory
diseases.
STATUS OF HTLV-1 EXPRESSION IN VIVO
The understanding of HTLV-1 expression in vivo has causedmuch
confusion, largely owing to two reasons: (a) HTLV-1 proteins are
not detectable in infected cells in the peripheral blood of HTLV-1
carriers; (b) two types ofATLcases exist, andwhileHTLV-1 expres-
sion in ATL cells is conserved in some cases, this expression is lost
in other cases (Figure 1).
EXPRESSION OF HTLV-1 PROTEINS IN VIVO
HTLV-1 mRNA but not proteins are detectable in the peripheral
blood mononuclear cells (PBMCs) of HTLV-1-infected individu-
als including ATL patients (Kinoshita et al., 1989). The presence
of HTLV-1 mRNA was also reported in other tissues such as mus-
cle in myositis patients (Tangy et al., 1995; Ozden et al., 2004)
or the spinal cord in HAM/TSP patients (Lehky et al., 1995).
Therefore, HTLV-1 gene expression does occur in vivo at least
at a transcriptional level. Furthermore, based on the ﬁndings that
HTLV-1-infected individuals maintain serum antibodies directed
to the HTLV-1 structural Env and Core proteins as well as Tax-
speciﬁc T-cells, HTLV-1 expression must be occurring also at a
protein level in vivo. This notion is further supported by the
emergence of Tax-speciﬁc CTL responses in ATL patients who
received hematopoietic stem cells from HTLV-1-negative donors
(Harashima et al., 2004, 2005). In these cases, the CTL responses
are presumably triggered by the de novo exposure of donor-
derived T-cells to Tax antigen in the recipients, and resemble
an acute infection. These ﬁndings suggest that the sensitivity of
T-cells recognizing HTLV-1 antigen may be much higher than
the detection by serological means such as ﬂow cytometry or
immunoblotting, which are dependent on antibody binding.
The conﬂicting arguments concerning HTLV-1 expression might
thus continue until more sensitive protein detection methods are
developed.
TWO TYPES OF ATL WITH OR WITHOUT HTLV-1 EXPRESSION
HTLV-1 expression in ATL cells immediately after isolation from
peripheral blood is very low, and becomes signiﬁcantly induced
only after in vitro cultivation (Hinuma et al., 1982).This phe-
nomenon is observed in about half of the ATL cases, regardless
of the severity of the disease (Kurihara et al., 2005). A similar
induction of viral expression after in vitro culture has also been
observed in PBMCs from HAM/TSP patients and ACs (Hanon
et al., 2000). Recent analysis using quantitative RT-PCR meth-
ods conﬁrmed this phenomenon in PBMCs from both ATL and
HAM/TSP patients. The data further showed that levels of Tax/Rex
mRNAwere increased as early as 4 h after initiation of culture, and
peaked at 8 h, followed by an increase in Env, Gag/Pol, and other
mRNAs (Rende et al., 2011). This ﬁnding is consistent with the
critical roles of Tax and Rex proteins for viral expression through
FIGURE 1 | Different status of HTLV-1 expression in infected
cells in vivo and in vitro. HTLV-1-infected cells express viral mRNA
in the peripheral blood and can express viral proteins in a short-term
culture in vitro (top). This phenomenon is observed in most
HTLV-1-infected individuals (top), but not in 1/2 cases of ATL
(bottom).
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transcriptional transactivation, regulation of RNA splicing, and
nuclear export of the mRNAs, which were described in previous
studies (Yoshida, 2001; Younis and Green, 2005). The rapid induc-
tion of viral expression in culture further suggests the presence of a
common mechanism transiently suppressing HTLV-1 expression
in vivo, irrespective of the disease.
In the remaining half of the ATL cases, however, such viral
induction does not occur, even after in vitro culture. This may be
due to genetic and epigenetic changes in the viral genome (Tamiya
et al., 1996; Takeda et al., 2004). The malignant phenotype of ATL
cells in these cases is presumably attributed to other mechanisms
acquired at additional steps of leukemogenesis, independently of
HTLV-1 expression.
EXPRESSION OF HBZ IN INFECTED CELLS
In uncultured PBMCs from HTLV-1-infected individuals, expres-
sion of the HTLV-1 genome is suppressed as noted above, whereas
mRNA of HBZ, the minus-strand HTLV-1-encoded gene, is con-
tinuously expressed, irrespective of the disease (Satou et al., 2006).
Transcription of HBZ in the absence of Tax implies an indis-
pensable role of HBZ in HTLV-1-infected cells. Interestingly,
mice carrying an HBZ transgene under the control of the CD4
promoter often develop lymphoproliferative disease with fre-
quent Foxp3 expression and inﬂammatory skin lesions (Satou
et al., 2011). These features partly resemble the characteristics
of ATL.
However, expression of HBZ at a protein level is still controver-
sial. In a study analyzing mRNA kinetics during the initial culture
of PBMC from infected individuals, Tax/Rex and other positive-
strand transcripts were promptly exported to the cytoplasm after
transcriptional induction, while HBZ mRNA was mostly retained
in the nucleus (Rende et al., 2011). In addition,HBZ-speciﬁc CTLs
induced in human leukocyte antigen (HLA)-A2-transgenic mice
lysed HBZ peptide-pulsed HLA-A2-positive target cells but not
HTLV-1-infected HLA-A2-positive cells (Suemori et al., 2009).
These observations suggest that expression of HBZ at a protein
level in HTLV-1-infected cells might be limited, even though sub-
stantial amounts of HBZ mRNA are expressed. Nevertheless, the
presence of T-cells responding toHBZpeptides have been reported
inHAM/TSP patients at a low frequency, implying a small amount
of HBZ protein synthesis in vivo (Hilburn et al., 2011).
HTLV-1 EXPRESSION IN HAM/TSP PATIENTS
HTLV-1 expression is detectable at the transcriptional, but not
the protein level in uncultured PBMCs, and such basal levels of
mRNA differ among diseases. An early study showed that the pX
mRNA/DNA ratio was lower in ATL patients compared with ACs
or HAM/TSP patients (Furukawa et al., 1995). This might partly
reﬂect that in 50% of ATL cases the cells lost viral gene expression,
as mentioned above. A recent study using a real-time quantitative
PCR analysis indicated that HTLV-1mRNA levels are signiﬁcantly
higher in HAM/TSP patients compared with ACs (Yamano et al.,
2002). This is in agreement with high levels of serum antibodies to
HTLV-1 in HAM/TSP patients (Dekaban et al., 1994). The detec-
tion of HTLV-1-speciﬁc antibodies in the cerebrospinal ﬂuid and
the pX mRNA in the spinal cord were also reported in HAM/TSP
patients (Lehky et al., 1995; Gessain, 1996). These observations
indicate that HTLV-1 expression is elevated in HAM/TSP patients
generally, and also in the spinal cord.
Little is known about the difference in the levels of HTLV-1
expression between tissues in humans. In transgenic mice car-
rying the pX gene driven by the HTLV-1 long terminal repeat
(LTR), RNA expression of the transgene is detectable only in
selectedorgans, including the central nervous system, eyes, salivary
glands, and joints (Iwakura et al., 1991). Transgenic mice and
rats with the pX gene often develop arthritis and other collagen-
vascular inﬂammatory conditions (Iwakura et al., 1991; Yamazaki
et al., 1997). This is partly explained by Tax-mediated activation
of NF-κB, a key transcription factor for multiple inﬂammatory
cytokine production. In addition, a certainWKAH strain exhibits
HAM/TSP-like symptoms after HTLV-1 infection. This rat model
of HAM/TSP shows increased Tax mRNA expression in the spinal
cord before the manifestation of the symptoms, suggesting that
viral expression in the spinal cord may be the primary event
(Tomaru et al., 1996). Reduced IFN-γ production in the spinal
cord has been suggested in this particular rat strain (Miyatake
et al., 2006).
DIFFERENT HTLV-1-SPECIFIC T-CELL RESPONSES
BETWEEN DISEASES
ANTI-TUMOR AND ANTI-VIRAL SURVEILLANCE BY
HTLV-1-SPECIFIC T-CELLS
The strength of the host T-cell response against HTLV-1 dif-
fers among diseases. CD8+ HTLV-1-speciﬁc CTL responses are
activated in HAM/TSP patients but not in ATL patients (Jacob-
son et al., 1990; Parker et al., 1992; Arnulf et al., 2004; Takamori
et al., 2011). These CTLs mainly recognize HTLV-1 Tax and kill
HTLV-1-infected cells in vitro (Jacobson et al., 1990) (Kannagi
et al., 1991). The HTLV-1 envelope protein is also a major tar-
get, especially for CD4+ CTLs (Goon et al., 2004). Other viral
antigens, including polymerase (Elovaara et al., 1993), TOF, ROF
(Pique et al., 2000), and HBZ, (Macnamara et al., 2010) have also
been shown to be targets of CTLs. Elimination of CD8+ cells from
the PBMCs from HAM/TSP patients induces HTLV-1 expression
during subsequent cell culture (Asquith et al., 2005), clearly indi-
cating that CD8+ HTLV-1-speciﬁc CTLs contribute to the control
of HTLV-1-infected cells.
A series of experiments using a rat model of HTLV-1-infected
T-cell lymphoma indicated that inhibition of the T-cell response
accelerated tumor development (Hanabuchi et al., 2000), and
further showed that vaccinationwith a Tax-encodingDNAor pep-
tides corresponding to a major epitope for Tax-speciﬁc CTLs lead
to the eradication of such tumors (Ohashi et al., 2000; Hanabuchi
et al., 2001). In a different rat model of HTLV-1 infection, oral
HTLV-1 infection induced HTLV-1-speciﬁc T-cell tolerance and
caused an elevation in the proviral load, while re-immunization
of these rats resulted in the recovery of HTLV-1-speciﬁc T-
cell responses and caused a reduction in the proviral loads
(Hasegawa et al., 2003; Komori et al., 2006).Similarly, patients car-
rying HTLV-1 developed ATL after liver transplantation, when
immunosuppressants were administered (Kawano et al., 2006;
Suzuki et al., 2006).These ﬁndings suggest that HTLV-1-speciﬁc
T-cells, especially Tax-speciﬁc CTLs, play important roles in
anti-tumor and anti-viral surveillance in HTLV-1 infection.
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The pathological signiﬁcance of HTLV-1-speciﬁc T-cells
activated in HAM/TSP patients remains controversial (Jacobson,
1995; Osame, 2002).Activated CTLs produce IFN-γ or TNF-α,
whichmight potentially participate in inﬂammation inHAM/TSP.
However, activation of Tax-speciﬁc CTLs could also merely be
a result of elevated viral expression in these individuals. HLA-
A02-positive individuals in HAM/TSP patients are less frequent
compared with the control population, indicating a protective
role of HLA-A02 against HAM/TSP. Since HLA-A02 can present
a major epitope of HTLV-1 Tax, the strong CTL response induced
is thought to mediate the protective effect of HLA-A02 (Jeffery
et al., 1999). The association of the protective HLAs with epitopes
favoring HBZ-speciﬁc CTLs has also been suggested (Macnamara
et al., 2010).
SELECTIVE IMPAIRMENT OF HTLV-1-SPECIFIC T-CELLS IN EARLY
STAGES OF ATL, A POTENTIAL RISK FOR ATL
We previously identiﬁed some major epitopes recognized by
HTLV-1-speciﬁc CTLs presented by HLA-A2, -A11, or -A24
through analysis of CTLs collected from ATL patients after
HSCT or collected from HAM/TSP patients (Kannagi et al., 1992;
Harashima et al., 2004, 2005).The identiﬁcation of these epitopes
allowed us to monitor HTLV-1-speciﬁc CTLs and analyze their
functions ex vivo by using antigen/HLA tetrameric complexes. In
our study using Tax-speciﬁc tetramers onHLA-A2, -A11, or -A24-
positive individuals, we detected Tax-speciﬁc CTLs in 100% of
HAM/TSP patients, 87% of ACs, and 38% of chronic ATL (cATL)
patients tested (Figure 2; Takamori et al., 2011).
It is interesting that Tax-speciﬁc CTLs were detectable also in
cATL patients, although their frequency among peripheral CD8+
cells is low. However, these CTLs were anergic as they neither
proliferated nor produced IFN-γ upon peptide stimulation. In
contrast, Tax-speciﬁc CTLs in HAM/TSP patients were highly
active even without stimulation, and their response was further
enhanced by stimulation.
Amongst ACs, Tax-speciﬁc CTLs are detectable in the major-
ity but not a small subset of individuals. Although Tax-speciﬁc
CTLs detected in ACs are mostly functional, sporadic AC cases
with impaired CTL responses to peptide-stimulation analogous
to ATL patients have been identiﬁed. Interestingly, such func-
tional impairment of CTLs seems selective to HTLV-1-speciﬁc
responses, as cytomegalovirus (CMV)-speciﬁc CTLs remain func-
tional (Figure 2; Takamori et al., 2011). Similar dysfunctions of
Tax-speciﬁc but not CMV-speciﬁc CTLs are found in smoldering
ATL, an early stage of ATL without clinically apparent lympho-
proliferation. These ﬁndings suggest that the scarcity and/or
dysfunction of Tax-speciﬁc CTLs are not merely the result of ATL,
but represent host conditions in a subset of HTLV-1 carriers at
FIGURE 2 | Selective loss or anergy ofTax-specific CTLs in a subset of
ACs. Incidences of Tax-speciﬁc CTL detection in CD8+ PBMC vary among
diseases (top). Tax-speciﬁc CTLs detected in HAM/TSP patients and most of
ACs (dark blue) were functional, while those in cATL patients and a subset of
ACs (light blue) were anergic to antigen stimulation. The CTL anergy was
selective for HTLV-1-speciﬁc response (bottom; Takamori et al., 2011).
Frontiers in Microbiology | Virology September 2012 | Volume 3 | Article 323 | 4
“fmicb-03-00323” — 2012/8/31 — 14:13 — page 5 — #5
Kannagi et al. Immune determinants of HTLV-1 pathogenesis
asymptomatic stages. A reduced number and/or dysfunction of
Tax-speciﬁc CTLs could thus represent an underlying risk factor
for the development of ATL.
Epidemiological studies indicated that increased numbers of
abnormal lymphocytes or HTLV-1 proviral loads are risk fac-
tors for the development of ATL (Tajima, 1990;Hisada et al.,
1998). However, elevated HTLV-1 proviral loads are also detected
in HAM/TSP patients, and do not discriminate risks for ATL
and HAM/TSP (Nagai et al., 1998).The immunological stud-
ies described above suggested that insufﬁciency in host T-cell
responses against HTLV-1 might be another risk factor for
ATL. We therefore suggest that the combination of elevated
proviral loads and low HTLV-1-speciﬁc T-cell responses may
represent a more selective indicator for the risk of develop-
ing ATL.
MECHANISMS OF T-CELL SUPPRESSION IN HTLV-1 INFECTION
It is known that ATL is often associated with severe immune
suppression (Tashiro et al., 1992), and a small number of stud-
ies reported general immune suppression also in ACs (Imai and
Hinuma, 1983). The mechanism of general immune suppres-
sion in these individuals is not known. ATL cells are positive for
CD4, CD25, CCR4, and frequently express Foxp3, all of which
match the phenotype of regulatory T-cells. If ATL cells function as
Treg cells, this would be a strong reason for the observed general
immune suppression (Karube et al., 2004). There are reports of
increased numbers of Foxp3-expressing Treg cells in the HTLV-
1-negative cell population in HAM/TSP patients (Toulza et al.,
2008). Recent studies reported that HBZ is potentially involved
in immune suppression by enhancing TGF-β signaling and
suppressing Th1 cytokine production (Zhao et al., 2011; Sugata
et al., 2012).
Asmentioned above, the insufﬁcient Tax-speciﬁc CTL response
observed in the early stages of ATL and in a subpopulation of
ACs was selective for the response to HTLV-1, and did not affect
CMV-targeting CTLs. From this differential effect we deduce
that other HTLV-1-speciﬁc suppressive mechanisms are active, in
addition to the general suppression. In general, antigen-speciﬁc
T-cell suppression can be induced by immune tolerance and T-cell
exhaustion. In HTLV-1 infection, vertical infection could be a rea-
son for T-cell tolerance. In animal models, oral HTLV-1 infection
induces T-cell tolerance to HTLV-1, resulting in increased levels of
proviral loads (Hasegawa et al., 2003). Since vertical infection of
HTLV-1 is established mainly through breast feeding (Kinoshita
et al., 1987), it may induce both new-born tolerance and oral
tolerance. This might partly explain the epidemiological ﬁnding
that vertical HTLV-1 infection is one of the risk factors for ATL
(Tajima, 1990).
Besides immune tolerance, T-cell suppression can also be
caused by T-cell exhaustion, which may be a consequence of
continuous expression of HTLV-1 antigens in vivo. Expression
of PD-1 in Tax-speciﬁc CTLs has been reported (Kozako et al.,
2009), although the involvement of this molecule in the suppres-
sion of CTLs in HTLV-1-infected individuals is still controversial
(Takamori et al., 2011). The relevance of other antigens remains
unknown, as for example recent studies revealed that Tax-speciﬁc
CTLs in HAM/TSP patients express reduced levels of Tim3, one of
the T-cell exhaustion markers, despite high viral gene expression
in these patients (Abdelbary et al., 2011; Ndhlovu et al., 2011).
IMPACT OF TYPE-I IFNs IN CONTROLLING
HTLV-1 EXPRESSION
INDUCTION OF TYPE-I IFN RESPONSE BY HTLV-1 INFECTION
Various viruses induce type-I IFN responses. In HTLV-1 infection,
however, the number of studies investigating a putative HTLV-1-
induced type-I IFN response is limited. One of the reasons is
that efﬁcient HTLV-1 infection is mediated mainly through cell–
cell contact. A recent report indicated that addition of cell-free
HTLV-1 particles propagated using an HTLV-1molecular clone to
plasmacytoiddendritic cells (pDCs) induced a type-I IFN response
through Toll-like receptor 7 (TLR7; Colisson et al., 2010). pDCs
are a major producer of type-I IFNs, and are reported to be
susceptible to HTLV-1 infection (Hishizawa et al., 2004; Jones
et al., 2008). In ATL patients, the number of pDCs is decreased,
and the remaining pDCs lack the ability to produce IFN-α
(Hishizawa et al., 2004).
At cell–cell contacts betweenHTLV-1-infected T-cells and stro-
mal cells, we found that HTLV-1 induced a type-I IFN response in
the stromal cells, suggesting an involvement of pattern recognition
molecules other than TLR7. However, the precise mechanisms of
HTLV-1-induced type-I IFN responses remain to be clariﬁed.
SUPPRESSION OF HTLV-1 EXPRESSION BY TYPE-I IFNs
HTLV-1 mRNA and protein expression in HTLV-1-infected T-
cells are markedly decreased when co-cultured with stromal cells
such as epithelial cells and ﬁbroblasts. This suppression of HTLV-
1 expression is inhibited by blocking the IFN-α/β receptor, and is
therefore thought to be mediated through type-I IFN responses
(Figure 3; Kinpara et al., 2009).
Interestingly, when infected cells were re-isolated from the co-
cultures, viral expression was restored to the original level over
the following 48 h (Figure 3). This phenomenon resembles the
induction of HTLV-1 expression in freshly isolated ATL cells after
culture in vitro. Type-I IFNs might therefore explain the long-
puzzling observation thatHTLV-1 expression is suppressed in vivo.
In support of this notion, viral expression inHTLV-1-infected cells
was signiﬁcantly suppressed when injected into wild-type mice
but not into IFN regulatory factor-7-knockout mice, which are
deﬁcient in most type-I IFN responses (Kinpara et al., 2009).
In general, type-I IFNs suppress viral replication mostly at
post-transcriptional level. SinceHTLV-1 transcription is regulated
by transactivation of its own LTR, mainly through cyclic AMP
(cAMP) response element-like repeats by the Tax protein (Fuji-
sawa et al., 1985; Sodroski et al., 1985), limitation of this protein
below a certain level will efﬁciently reduce HTLV-1 expression
to a basal level. Involvement of inducible cAMP early repressor
(ICER) and transducer of regulated CREB protein 2 (TORC2) in
the inhibition of HTLV-1 transactivation has also been suggested
(Newbound et al., 2000; Jiang et al., 2009).
Addition of IFNs alone also elicits suppressive effects inHTLV-1
expression. However, the levels of suppressive effects differ among
studies. In HTLV-1-infected cell lines, it has been reported that
IFN-α2a decreased HTLV-1 assembly and viral release but not
viral protein synthesis (Feng et al., 2003).
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FIGURE 3 | Reversible suppression of HTLV-1 expression by stromal
cells through type-I IFNs. HTLV-1 protein expression in HTLV-1-infected
T-cells are markedly decreased when co-cultured with stromal cells and
recovers after re-isolation from the co-cultures (Kinpara et al., 2009).
RESISTANCE OF HTLV-1 AGAINST TYPE-I IFN SIGNALING
As is the case with many other viruses, HTLV-1 has developed
strategies to evade IFN responses. It has been reported that
HTLV-1 infection reduces the phosphorylation of tyrosine kinase
2 (TYK2) and signal transducer and transcriptional activator 2
(STAT2; Feng andRatner, 2008), and that Tax inhibit the induction
of IFN-stimulated genes (ISGs) by competing with CREB binding
protein/p300 (Zhang et al., 2008). Recent reports also suggest that
Tax-mediated up-regulation of suppressor of cytokine signaling 1
(SOCS1) inhibits IFN signaling (Oliere et al., 2010; Charoenthong-
trakul et al., 2011). However, expression levels of Tax protein are
low in vivo, and it is unclear towhat extent the evadingmechanisms
observed in vitro are effective in vivo.
It has been reported that a combination therapy of AZT and
IFN-α is effective for the treatment of ATL (Hermine et al., 1995),
indicating that HTLV-1-infected cells retain some susceptibility
to IFNs in vivo. Intriguingly, this combination of AZT/IFN-α
does not affect HTLV-1-infected cells in vitro (Bazarbachi et al.,
2000), and the mechanistic effect of this therapy is not known.
The discrepancy in the therapeutic effects in vivo and in vitro is
presumably due to the different status of HTLV-1-infected cells in
the two systems.
AZT/IFN-α is not a radical therapy, and ATL relapses are fre-
quently observed after cessation of the therapy (Hermine et al.,
2002), suggesting that AZT/IFN-αmay not be cytocidal but rather
has static effects on infected cells. Another combination therapy
of arsenic trioxide and IFN-α shows more favorable therapeutic
effects in vivo, and also shows proteolysis of Tax in HTLV-1-
infected cells in vitro (ElHajj et al., 2010). IFN-α or β alone appears
less effective for the treatment of HAM/TSP, but does show some
therapeutic effects, especially during the early stages of HAM/TSP
(Izumo et al., 1996; Saito et al., 2004).
IFN RESPONSES IN HTLV-1-INFECTED INDIVIDUALS
A recent study revealed up-regulation of SOCS1 in CD4+ cells
of HAM/TSP patients, which caused enhanced viral expression
through inhibition of type-I IFN signaling (Oliere et al., 2010).
At the same time, a different study showed that HTLV-1 Tax up-
regulates SOCS1 (Charoenthongtrakul et al., 2011). These ﬁndings
indicate that up-regulation of SOCS1 might be a result and/or
cause of enhanced viral expression in HAM/TSP. Another recent
study using gene expression array analysis reported up-regulation
of a subset of ISGs, including STAT1, CD64, FAS, and CXCL10,
especially in the neutrophil and monocyte fractions from periph-
eral blood of HAM/TSP patients (Tattermusch et al., 2012). This
suggests that type-I IFN responses were induced in these cell pop-
ulations directly or indirectly by HTLV-1, although type-I IFN
production in these cells was not clear. The strongHTLV-1-speciﬁc
T-cell response in these patients might also cause such effects
through IFN-γ production.
The signature of IFN responses in the peripheral blood of
HAM/TSPpatients left an unanswered questionwhat enhances the
basal level of viral expression in these patients. Increased inﬂam-
matory cytokines in HAM/TSP patients might be candidates to
enhance viral expression, but again these could be a result and/or
cause of enhanced HTLV-1 expression.
THE RELATIONSHIP AMONG VIRAL EXPRESSION, HOST
IMMUNITY, AND VIRAL PATHOGENESIS
It is speculated that the status of viral expression and host immu-
nity may differ among various tissues in vivo. Therefore, it is
difﬁcult to estimate HTLV-1 status in the entire body based on
the information gained only from peripheral blood. Neverthe-
less, the recent ﬁndings about innate immunity described above
provide clues as to how the current knowledge around HTLV-1
expression and host immunity can be integrated, especially when
they so closely interact and have both causes and effects on each
other.
Type-I IFNs are likely to be the representative factor to control
HTLV-1 expression, and HTLV-1-speciﬁc T-cells survey infected
cells to limit their growth. The suppression of viral expression
might interfere with the efﬁcacy of HTLV-1-speciﬁc T-cells by
reducing the levels of target molecules, even in hosts with a
functional HTLV-1-speciﬁc T-cell response. The resulting low efﬁ-
ciency of T-cell surveillance would be one of the mechanisms
behind persistent HTLV-1 infection, although it seems that T-
cells would still contribute to the control of HTLV-1-infected cell
growth to some extent.
Despite the negative impact on T-cell surveillance, the sup-
pression of viral expression is important for the host to reduce
viral pathogenesis since Tax has a strong ability to activate NF-κB,
which is critical for the induction of inﬂammation or cell growth
signaling.
Frontiers in Microbiology | Virology September 2012 | Volume 3 | Article 323 | 6
“fmicb-03-00323” — 2012/8/31 — 14:13 — page 7 — #7
Kannagi et al. Immune determinants of HTLV-1 pathogenesis
FIGURE 4 | Hypothetical relationship of the host immune balance to the
status of HTLV-1-infected cells and viral pathogenesis. If viral expression is
well controlled (barrier 1: intact), the viral pathogenesis may not be apparent
until malignant cell clones appear throughT-cell surveillance (barrier 2). If the
T-cell defense is insufﬁcient (barrier 2: weak), the emergence of such clones
may occur earlier. If the viral expression is not well controlled (barrier 1:
weak), virus-induced inﬂammation may become apparent, but it also activates
HTLV-1-speciﬁc T-cells that limit further growth of infected cells.
Supposing that the suppression of viral expression is the ﬁrst
barrier and T-cell surveillance of infected cells is the second barrier
in the host defense, the balance of these barriers would inﬂuence
the status of HTLV-1-infected cells in vivo. A conceivable scenario
is as follows (Figure 4).
If viral expression is well controlled, the viral pathogenesis may
not be apparent until malignant cell clones appear through the
process of clonal evolution in the infected cell reservoir. Thismight
explain the long incubation time for ATL development. In the
absence of effective T-cell responses, the emergence of such clones
may occur earlier, as clonal survival may be more likely.
In contrast, if the suppression of viral expression is insufﬁcient,
either by insufﬁcient IFN response or increased inﬂammatory
cytokines, viral pathogenesis will become apparent and symptoms
will be exhibited, especially in the tissues where viral proteins
reach functional levels. In this case, however, the elevated levels of
viral expressionwould also activateHTLV-1-speciﬁcT-cells, which
potentially limit further growth of infected cells.
CONCLUSION
The status of HTLV-1-speciﬁc T-cell response has been shown
to be a determinant of HTLV-1-mediated diseases because of its
anti-tumor and anti-viral effects. The selective impairment of
HTLV-1-speciﬁc T-cell responses in early stages of ATL patients
implies the presence of HTLV-1-speciﬁc suppressive mechanisms.
The combination of insufﬁcient HTLV-1-speciﬁc T-cell response
and elevated proviral load may allow the identiﬁcation of a
group with a high risk for the development of ATL. In addi-
tion, vaccines that augment HTLV-1-speciﬁc T-cell responses
may prove beneﬁcial in reducing the risk in such a subpopu-
lation.
The status of HTLV-1 expression can be another determinant of
HTLV-1-mediated diseases. Suppression of viral expression con-
tributes to reduced viral pathogenesis, although it may, at the
same time, partially interfere with T-cell surveillance. Host innate
immunity, especially type-I IFN, is a candidate for the regulation
of viral expression.
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Thus, both acquired and innate immunity can be host
determinants that modulate HTLV-1-associated diseases. The
involvement of the two control systems and their partially
conﬂicting effects on one another may explain why the same
virus can cause different diseases after a long incubation
time. Further studies will elucidate the precise mechanisms
for the regulation of host immunity and viral expression, and
thereby provide insights for the prediction of disease risks, as
well as new targets for the prevention of HTLV-1-mediated
diseases.
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